Sector News

Baxter pads biopharma unit with pre-spinoff oncology buy

May 13, 2015
Life sciences
As Baxter gears up to spin off its biopharma unit into new company Baxalta, it wants to make sure the new pharma has enough revenue to rely on. And to do that, it’s bulking up.
 
The Illinois company has agreed to purchase leukemia treatment Oncaspar from Italy’s Sigma-Tau Finanziaria for $900 million, it said Tuesday. The therapy–part of a first-line chemo regimen to treat acute lymphoblastic leukemia (ALL)–will play a key role in Baxalta’s oncology division, Baxter said, with $100 million in annual sales from countries including the U.S., Germany and Poland.
 
“The acquisition provides an immediate commercial footprint in the United States and Europe with a heritage of expertise in treating this challenging disease,” David Meek, Baxter BioScience’s head of oncology, said in a statement.
 
And Baxter won’t stop there. It plans to investigate Oncaspar for potential new indications, it said, both in ALL and other cancers–including acute myeloid leukemia.
 
Baxter’s not the only company shelling out to get in on the booming oncology market. In March, AbbVie agreed to fork over $21 billion for Pharmacyclics, which markets blood cancer drug Imbruvica with partner Johnson & Johnson. And a few days prior, Novartis  closed its $16 billion pickup of GlaxoSmithKline’s cancer assets.
 
For Baxter, whose biopharma business relies heavily on its hemophilia drugs, cancer meds will be an important sales source. The company thinks the oncology sector represents $10 billion in total market potential for its pipeline assets, it said–and with two new, long-lasting Biogen challengers to its leading hemophilia products out there, that’s revenue Baxalta could use.
 
By Carly Helfand
 

comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach